An established safety profile that comes from experience.^a

“Recombinant” means that the product is made in a laboratory. Recombinant factor products were developed in the 1990s after thousands of people with hemophilia contracted Hepatitis C or were infected with HIV through contaminated factor products derived from human blood or plasma.

Before recombinant products were developed, the only treatments available to manage bleeding disorders were derived from the human blood supply, which carries a risk of blood-borne viruses or pathogens.

Recombinant factor products are manufactured in a laboratory, without human-derived components. NovoSeven^® RT undergoes a rigorous 5-step process to ensure safety.

1. Cell Bank
Cells are created that produce clotting factor identical to that occurring naturally in the human body.

2. Production
Clotting factor is made by cells grown under careful lab conditions.

3. Purification
A cleansing process removes any remaining impurities.

4. Preparation
The factor is prepared for long-term storage.

5. Quality control
A final inspection helps ensure a high-quality product.

Clinical trials show that NovoSeven^® RT patients experienced a low rate of blood clots.

• 0.2% of bleeding episodes in people with hemophilia A or B with inhibitors
• 4% rate in people with acquired hemophilia

The most common and serious side effects of NovoSeven^® RT are blood clots. Serious blood clots that form in veins and arteries with the use of NovoSeven^® RT have been reported. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.